GlassScriptPhysician profile
Sneha Arjun Agarwalla
NPI 1801245162
$4,577.15
in general payments reported to CMS, 2019-2025
31 companies · $1,391 in 2025
The $1,391 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $156 · 2021: $56.45 · 2022: $781 · 2023: $1,241 · 2024: $952 · 2025: $1,391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,584.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,583.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $478.78 | 2023-2025 | |
| Pfizer INC. | $431.00 | 2020-2025 | |
| Amgen INC. | $390.59 | 2022-2025 | Repatha, Repatha |
| Scpharmaceuticals INC. | $309.22 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $295.67 | 2022-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $282.58 | 2022-2024 | Watchman Flx, Watchman Access System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $278.41 | 2023-2025 | Jardiance |
| Novo Nordisk INC | $257.31 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $170.77 | 2022-2025 | Farxiga, Wainua |
| Abbott Laboratories | $168.32 | 2022-2023 | Cardiomems |
| Abiomed | $160.54 | 2022-2025 | Impella |
| Lilly USA, LLC | $154.17 | 2023-2025 | Jardiance, Mounjaro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $127.29 | 2022-2023 | Lifevest |
| Lexicon Pharmaceuticals, INC. | $119.65 | 2023-2024 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $103.86 | 2023-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $86.94 | 2024 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $82.21 | 2022-2025 | Onpattro |
| Janssen Pharmaceuticals, INC | $80.63 | 2022-2024 | Xarelto |
| Esperion Therapeutics, INC. | $80.61 | 2024-2025 | Nexletol |
| Astellas Pharma US INC | $75.00 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $71.90 | 2023 | Arcalyst |
| Merck Sharp & Dohme LLC | $60.92 | 2022-2024 | Verquvo |
| Actelion Pharmaceuticals US, INC. | $60.33 | 2025 | Opsumit, Uptravi |
| Bridgebio Pharma, INC. | $58.12 | 2025 | Attruby |
| Amarin Pharma, INC. | $55.29 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $39.94 | 2022 | |
| Chiesi USA, INC. | $29.91 | 2025 | Juxtapid |
| Medtronic, INC. | $18.37 | 2022 | |
| Impulse Dynamics (USA) INC. | $18.15 | 2024 | Optimizer |
| Heartflow, INC. | $17.08 | 2023 | Ffrct |
| Kowa Pharmaceuticals America, INC. | $13.59 | 2023 | Livalo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sneha Agarwalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.